REZDIFFRA
resmetiromsmall moleculethyroid hormone receptor-β agonist
MASH (NASH)
Approved
1 program·1 trial·View drug →
DashboardBuy26,465$41.46+$1.1MOption ex.7,917$47.27$374.3K Internal MedicineResearch Grant$420.5K6Internal MedicineEquity / Ownership$312.1K7Internal MedicineCo-Investigator$290.4K6EndocrinologyResearch Grant$273.3K4EndocrinologyResearch Grant$172.1K3Internal MedicineCo-Investigator$150.1K2Internal MedicineEquity / Ownership$122.9K2EndocrinologyConsulting$49.0K6Internal MedicineSpeaking$19.7K3Internal MedicineSpeaking$18.2K3
MDGLNASDAQ
Madrigal
Madrigal Pharmaceuticals, Inc. · West Conshohocken, PA · founded 2011
Madrigal Pharmaceuticals is a West Conshohocken, Pennsylvania single-asset biotech focused on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), a progressive liver disease driven by fat accumulation, inflammation, and scarring. Its drug REZDIFFRA (resmetirom) is a once-daily oral thyroid hormone receptor-beta agonist and the first FDA-approved therapy for non-cirrhotic MASH with significant fibrosis.
- Lead asset
- REZDIFFRA · Approved · MASH (NASH)
- small molecule · thyroid hormone receptor-β agonist
- Pipeline
- 1 drug · 1 program
- 1 NASH / MASH
- Modalities
- small molecule×1
FocusNASH / MASH
$290.00+43.27%1Y
MDGL · daily close · illustrative · 1 catalyst marked
Interim+12%
1Y high$292.531Y low$188.63range$103.90(55%)past catalysts
Peers in this space
AKRO$2.4B
Akero Therapeutics
Rel.
0.58
NASH / MASHbiologic
1 programmatch: sector
BMY$105.0B
Bristol Myers Squibb
Rel.
0.65
Cardiology - HFpEFsmall molecule
1 programmatch: modality
INCY$14.6B
Incyte
Rel.
0.72
Oncology - Hemesmall molecule
1 programmatch: modality
BPMC$6.1B
Blueprint Medicines
Rel.
0.49
Oncology - Solidsmall molecule
1 programmatch: modality
AXSM$4.2B
Axsome Therapeutics
Rel.
0.58
Neurologysmall molecule
1 programmatch: modality
FOLD$2.9B
Amicus Therapeutics
Rel.
0.59
Rare Diseasesmall molecule
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
May 30, 2025InterimREZDIFFRA — Phase 3 Interim — Stopped for EfficacyPositive+11.8%+11.2%+14.9%
Jul 4, 2024ReadoutREZDIFFRA — Phase 2b Topline Met Primary EndpointPositive+20.0%+39.4%+37.6%
Jul 4, 2024PDUFAREZDIFFRA — PDUFA — CRL IssuedNegative-19.6%-35.0%-31.8%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 2 transactions · 2 insiders
Net flow
+$1.1M
Buys
$1.1M
1 txns
Sells
$0
0 txns
Largest
+$1.1M
EVP buy
Net flow per quarter · last 8Q
5 txns · sum −$4.22M
24Q325Q125Q326Q126Q2
buys · $1.10Msells · $5.32M
Insider · roleActionSharesPriceValueDate
J. Mendoza
EVP
Apr 22, 2026
B. Kowalski
Director
Feb 15, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
6 trades · 6 members
Est. net flow
−$2.84M
midpoint · brackets only
Buys
4
Sells
2
Party mix
4 D2 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
R
Buy$250K–$500K~$375KjointRep. M. Hartwell
House · FL
Mar 30, 2026
filed +19d
R
Buy$50K–$100K~$75KselfRep. G. Ostrom
House · OH
Mar 16, 2026
filed +42d
D
Buy$1K–$15K~$8KdependentRep. H. Patel
House · IL
Feb 16, 2026
filed +32d
D
Partial sell$250K–$500K~$375KselfSen. A. Reyes
Senate · CA
Jan 23, 2026
filed +20d
D
Buy$50K–$100K~$75KselfRep. P. Bowen
House · NJ
Dec 15, 2025
filed +33d
D
Partial sell$1.00M–$5.00M~$3.00MselfRep. L. Marquez
House · NM
Jun 16, 2025
filed +38d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
3 ETFs hold the position
Held by ETFs
$25.9M
aggregate position
Of market cap
0.38%
aggregate ETF share
Top holder
XBI0.26%
SPDR S&P Biotech ETF
TickerETF · familyThemeNAV% of NAVPosition
XBIBroad biotech$7.90B0.26%$20.5M
SPDR S&P Biotech ETF
SPDR
SBIOSmall-cap biotech$110.0M4.46%$4.9M
ALPS Medical Breakthroughs ETF
First Trust
BBCSmall-cap biotech$60.0M0.84%$504K
Virtus LifeSci Biotech Clinical Trials
WisdomTree
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
12 physicians paid · 46 disclosed records
Total 2025+2024
$1.85M
YoY
-8%
Equity / Ownership$704.5KResearch Grant$535.9KCo-Investigator$347.9KConsulting$134.7KSpeaking$84.5KTravel & Lodging$37.2KFood & Beverage$1.0K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Kavya Davies
Penn Medicine
Dr. Marcus Lindberg
MD Anderson
Dr. Sarah Iyer
Memorial Sloan Kettering
Dr. Olivia Mendoza
Cedars-Sinai
Dr. Theo Park
Cedars-Sinai
Dr. Nadia Park
Cedars-Sinai
Dr. Ahmed Tanaka
Duke University
Dr. Priya Nakamura
Yale Medical
Dr. Kavya Tanaka
Vanderbilt
Dr. Theo Murphy
Memorial Sloan Kettering
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$359K disclosed · 2 firms engaged
YoY change
+35%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Mehlman Castagnetti$218K
7 quarters active
Forbes-Tate Partners$141K
5 quarters active
Top issues lobbied
- Pharmacy Benefit Manager (PBM) reform$218K
- Accelerated approval pathway reforms$71K
- BIOSIM Act / Biosimilars$71K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
2 awards · 2 agencies
Total awarded
$172.3M
across all programs
Active
$126.5M
option periods incl.
Top agency
BARDA$126.5M
largest active: Medical Countermeasure Stockpiling
AgencyTitle · type · award IDStatusValueAwarded → ends
BARDAactive$126.5MNov 2025→ Oct 2028
Medical Countermeasure Stockpiling
Contract · BAR-38403764
DoD / DARPAcompleted$45.9MJul 2023→ Jan 2026
Genome Editing Therapeutics — Pandemic Response
BAA / OTA · DDD-13352231
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
4 granted · 2 pending
Total in portfolio
6
Granted in last 12mo
0
Expiring < 2yr
0
Nearest expiry
Apr 2033
Patent #Title · inventor · drugTypeStatus · filedExpiry
US 2025/1879331 A1Composition of Matter
Therapeutic peptide compositions for REZDIFFRA
S. Greene + 3 · REZDIFFRA
pendingfiled Apr 2025
in prosecution
10,880,213Formulation
Pre-filled syringe formulations comprising REZDIFFRA
P. Nguyen + 4 · REZDIFFRA
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
11,665,897Process
Purification methods for REZDIFFRA
K. Walsh + 1 · REZDIFFRA
grantedfiled Apr 2018
exp. Apr 2038
12.0y left
US 2021/0172581 A1Process
Recombinant production of therapeutic REZDIFFRA
J. Andersson + 1 · REZDIFFRA
pendingfiled Apr 2021
in prosecution
11,271,588Formulation
Sustained-release oral compositions of REZDIFFRA
R. Davies + 2 · REZDIFFRA
grantedfiled Apr 2016
exp. Apr 2036
10.0y left
12,311,999Process
Recombinant production of therapeutic REZDIFFRA
A. Andersson · REZDIFFRA
grantedfiled Apr 2013
exp. Apr 2033
7.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
8 items from 4 categories
regulatory3corporate2lawsuit2clinical1
13d ago
MDGL announces $280 million private placement
PR Newswire·corporate
22d ago
FDA accepts MDGL's NDA for REZDIFFRA; PDUFA date set
FierceBiotech·regulatory
2mo ago
MDGL expands manufacturing capacity at lead facility
Business Wire·corporate
2mo ago
MDGL settles patent litigation with Ranbaxy successor
Reuters·lawsuit
2mo ago
Class-action complaint filed against MDGL alleging disclosure issues
STAT$·lawsuit
2mo ago
EMA validates MDGL's Marketing Authorization Application for REZDIFFRA
Endpoints News$·regulatory
3mo ago
MDGL doses first patient in Phase 3 REZDIFFRA study
FierceBiotech·clinical
3mo ago
FDA accepts MDGL's NDA for REZDIFFRA; PDUFA date set
FierceBiotech·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$290.00
Open
$289.13
Day Δ
+0.87
+0.30%
Day range
$286.96 – $292.17
52W range
$188.63 – $292.53
Avg daily volume
267K
Valuation & ownership
Enterprise value
$6.2B
Shares out
23.45M
Float
20.87M
Insider %
5.32%
Institutional %
50.32%
Beta
1.82
vs SPY · 52w
Balance sheet & burn
Cash + invest
$1.1B
Total debt
$388M
Debt / equity
7.32
Cash burn / Q
$77M
R&D spend TTM
$285M
26% of cash
ATM available
$1.2B
dilution risk
Earnings
EPS latest
$-0.27
EPS Δ vs prior
+0.12
EPS estimate
$-0.15
next quarter
EPS prior
$-0.39
Next earnings
May 10, 2026
Rev guidance
$184M